A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Clinical trial NCT03345082 · COMPLETED

Trial details

NCT number: NCT03345082
Sponsor: Opthea Limited
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Neovascular Age-related Macular Degeneration

Start date: 2017-11-06
Primary completion: 2019-05-14
Enrollment: 366

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.